Danaher Collaborates with Microsoft to Make Scientific Instruments Agentically Connected and Laboratories More Intelligent

Advancing autonomous science through smart scientific instruments and an interoperable agentic ecosystem

WASHINGTON — Danaher Corporation (NYSE: DHR) today announced a strategic partnership with Microsoft to support the development of smart scientific instruments and an interoperable agentic ecosystem that connects technologies across Danaher while remaining open to the broader laboratory ecosystem, helping scientists move from scientific questions to experimental evidence faster. The partnership seeks to combine Danaher’s scientific, workflow and instrumentation expertise with Microsoft’s AI technologies, making experimental execution more streamlined and insights more readily available to translate discovery into human impact.

The partnership is focused on accelerating the development of a common agentic platform for instrument control and insight generation. The platform is built on Microsoft technology: Microsoft Azure for secure, compliant cloud infrastructure, and Microsoft Foundry to power the AI agents that interpret results and guide instrument control. Its goal is to enable reuse and interoperability across technologies, so specialized products can be built on a shared foundation, while remaining open to agents and digital solutions in multi-vendor laboratories.

While the companies are continuing to develop this platform, the first commercial applications will reach Danaher customers this year, including MetaXpress Acquire AI Assistant, Molecular Devices’ software for its high-content cellular imaging systems, designed to provide product support. Additional next-generation, agent-enabled instruments from Danaher businesses that use this platform are planned for 2027.

“Danaher’s businesses bring deep scientific and instrument expertise to customers every day,” said Julie Sawyer Montgomery, President and CEO of Danaher. “With Microsoft, we are building a common foundation, so our instruments and laboratories work together consistently, as one connected Danaher. Through context and learning, that foundation can continuously inform the next experiment and the best analysis. This partnership is an important step toward making laboratories not just connected, but intelligent.”

As part of this partnership, smart, agent-enabled instruments are being designed with the goal of supporting scientists across four critical activities:

• Translating scientific intent into experimental plans, instrument setup and methods
• Controlling instrument hardware within defined safety boundaries and with user oversight, while guiding execution and troubleshooting
• Interpreting results and identifying quality issues in real time
• Recommending corrective actions and next experiments for scientist review

AI-assisted instruments are intended to simplify complex scientific workflows. In preliminary internal testing, novice scientists conducting an AI-assisted experiment on a Leica microscope took up to 83% less time and up to 68% fewer steps to complete than a novice working without the AI assistant, while producing high-quality data and completing the experiment in a time comparable to an expert.

“Danaher’s scientific expertise, combined with Microsoft’s AI platform, aims to give scientists more choice and control, and more time for discovery,” said Deb Cupp, Executive Vice President and Chief Revenue Officer, Microsoft Global Enterprise. “This partnership aligns with our goal to help translate AI into real-world impact.”

The partnership is designed to advance Danaher’s broader strategy for AI and autonomous science by connecting intelligence at the instrument with data, laboratory workflows and the physical execution of experiments. Intelligent instruments are a first step. As instruments and laboratory systems become more connected and interoperable, Danaher believes experimental results can help scientists determine what to do next, supporting discovery through increasingly connected and autonomous workflows under scientific oversight.

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2026.
These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

ABOUT DANAHER
Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com.
SOURCE Danaher Corporation

< |